Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Commingling of licenses

Pursuant to Moore's complaint:

47. TPL has failed since Sept. 16, 2006 to exert reasonable efforts to commercialze the MMP and has commingled licensing efforts & licenses to third party ...assigning MMP technologies a disproportionately small share of toal license revenues w/o Moore's knowledge or consent.

Do you realize that only about 8-10 licenses were signed prior to Sept. 16, 2006. If, as Moore believes, TPL not only failed to commercialize the MMP but had been commingling licensing efforts and assigning a small share of revenue to the MMP since that date...

Did our BoD know or suspect this was happening for so long? Why did it take until April 2010 to file a complaint against TPL? What safety mechanisms are now in place since the settlement agreement to prevent this from ever happening again?

If MMP was assigned a small share of licensing revenues due to commingled license efforts since Sept. 16, 2006....what is PTSC doing to to ensure that the correct share of revenues is paid back to the company?

Share
New Message
Please login to post a reply